Skip to main content

Table 3 Clinical characterestics, co-morbidities and medications in HFrEF and HFpEF subgroups

From: Clinical characteristics and in-hospital outcome of heart failure in women: a single center registry from Egyptian cardiac care unit

  HFrEF, n = 73 HFpEF, n = 45 P value
Age (years) 66.9 ± 9 52.3 ± 11 0.0001
Chest pain (CP) 22 (30%) 1 (2.22%) 0.001
Killip class    
 I 7 (9.6%) 4 (9%) 0.935
 II 4 (5.5%) 2 (4.44%) 0.915
 III 16 (22%) 11 (24.44%) 0.887
 IV 44 (60.3%) 27 (60%) 0.941
Orthopnea 50 (68.5%) 30 (66.67%) 0.932
PND 12 (16.4%) 4 (9%) 0.488
Palpitations 3 (4.12%) 11 (24.44%) 0.004
Syncope 1 (1.4%) 0 (0%) 0.692
Cough dry 3 (4.12%) 5 (11.11%) 0.142
Productive cough 19 (26%) 11 (24.44%) 0.339
Edema 26 (35.6%) 12 (26.67%) 0.256
Previous MI 13 (17.8%) 6 (13.33%) 0.500
Previous PCI 9 (12.3%) 3(6.67%) 0.380
Previous CABG 7 (9.6%) 1(2.22%) 0.190
Valve surgery 1 (1.4%) 5(11.11%) 0.035
STEMI 16 (21.9%) 0 (0%) 0.002
STEMI 16 (21.9%) 0 (0%) 0.002
UA/NSTEMI 8 (11%) 13(28.9%) 0.000
CHB 1 (1.34%) 0 (0%) 0.436
AF/flutter 10 (13.7%) 12 (26.6%) 0.039
IE 0 (0%) 1 (2.2%) 0.077
PE 1 (1.34%) 2 (4.44%) 0.303
Aortic dissection 1 (1.34%) 2 (4.44%) 0.303
Hypertension 4(5.5%) 11(24.44%) 0.000
Prior HF 20 ( 27%) 8 (17.78%) 0.000
RHD 0 (0%) 4 (8.89%) 0.000
Pacemaker 1 (1.4%) 2 (4.44%) 0.108
ICD 1 (1.4%) 0 (0%) 0.436
CVP 52 (71.2%) 19 (42.2%) 0.002
Endotracheal intubation 15 (20.5%) 0 (0%) 0.001
Thazides 22 (12.4%) 8 (6.8%) 0.119
Loop diuretics 109 (61%) 68 (57.6%) 0.535
Nitrates 103 (58%) 67 (56.78%) 0.853
Warfarin 63 (35.4%) 31 (26.3%) 0.099
Clopedogril 75 (42.1%) 58 (49.2%) 0.235
Hospital stay 7.88 ± 5.7 5.73 ± 3.4 0.02
Sepsis 1 (1.4%) 2 (4.4%) 0.303
Pneumonia 4 (5.5%) 2 (4.44%) 0.575
Fever 0 (0%) 1 (2.22%) 0.172
Hemoptesis 1 (1.4%) 0 (0.85%)  
Lanoxin toxicisty 0 (0%)
0 (0%)
1 (2.22%)
1 (2.22%)
 
CKD/ESRD 3 (4.12%) 0 (0%) 0.236
Respiratory failure 2 (2.7%) 2 (4.44%) 0.511
liver failure 3 (4.12%) 6 (13.3%) 0.067
Tamponade 1 (1.4%) 2 (4.44%) 0.303
GIT bleeding 1 (1.4%) 2 (4.44%) 0.303
CCI 71 (97.3%) 41 (91%) 0.140
Previous MI 13 (17.8%) 4 (4.44%) 0.261
AKI 12 (16.4%) 0 (0%) 0.016
PVD 1 (1.4%) 1 (2.22%) 0.549
CVA/TIA 7 (9.6%) 3 (6.7%) 0.518
Hemiplegia 2 (2.7%) 0 (0%) 0.322
COPD 7 (9.6%) 3 (6.67%) 0.056
Autoimmune 8 (11%) 0 (0%) 0.046
Mild liver diseases 1 (1.4%) 0 (0%) 0.436
peptic ulcer 0 (0%) 1 (2.22%) 0.254
Cancer 1 (1.4%) 0 (0%) 0.436
Metasis 1 (1.4%) 2 (4.4%) 0.303
Dementia 1 (1.4%) 2 (4.44%) 0.336
Rheumatic D 1 (1.4%) 2 (4.4%) 0.303
HIV 0 (0%) 1 (2.22%) 0.254
Cellulitis 3 (4.12%) 6 (13.%) 0.067
Depression 0 (0%) 2 (4.4%) 0.108
Mechanical ventilation 14 (19.2%) 1 (2.22%) 0.007
Pricardiocentesis 0 (0%) 1 (2.22%) 0.201
PCI 7 (9.6%) 0 (0%) 0.032
Coronary angiography 5 (6.8%) 0 (0%) 0.073
Amiodarone 17 (9.6%) 7 (14.4%) 0.200
Unfractunated heparin 62 (34.8%) 34(28.8%) 0.279
LMWH 100 (56.2%) 79 (67%) 0.064
Lytic therapy 45 (25.3%) 32 (27.1%) 0.724
Mortality 12 (16.4%) 1 (2.22%) 0.01
  1. BMI body mass index, DM diabetes mellitus, HTN hypertension, STEMI ST segment elevation myocardial infarction, UA unstable angina, IE infective endocarditis, PE pulmonary embolism, CHB complete heart block, Af atrial flutter, AF atrial fibrillation, PCI percutaneous coronary intervention, CA coronary angiography, CVA cerebrovascular accident, HR heart rate, SBP systolic blood pressure, DBP diastolic blood pressure